Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Efficacy and Tolerability of Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer Patients With FGFR Mutation

NCT04936295 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04936295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04936295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Efficacy and Tolerability of Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer Patients With FGFR Mutation
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
June 16, 2021
Completion date
June 1, 2025
Enrollment
61 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer